Orexigen Therapeutics Commends the Campaign to End Obesity's Report on Long-term Returns of Obesity Prevention Policies

    Orexigen Therapeutics Commends the Campaign to End Obesity's Report on
               Long-term Returns of Obesity Prevention Policies

PR Newswire

SAN DIEGO, April 25, 2013

SAN DIEGO, April 25, 2013 /PRNewswire/ --Regarding the report "The Long Term
Returns of Obesity Prevention Policies" unveiled this week by the Campaign to
End Obesity (CEO), Orexigen Therapeutics, Inc. (Nasdaq: OREX) issued the
following statement:

Orexigen commends CEO as well as the author of the report, Alex Brill, and the
Robert Wood Johnson Foundation (RWJF) who funded the report, for this new
research illustrating the importance of long-term budget impact analyses on
preventive health policies, specifically those aimed at obesity. With obesity
contributing over $200 billion annually to healthcare spending, Orexigen
agrees that policymakers needthorough budgetary analyses that capture short
and long-term impacts of obesity policy. A longer view may enable policymakers
to have more information when making legislative decisions. Brill noted that
the largest budgetary benefits from reducing the burden of obesity would be
federal savings within the Medicare and Medicaid programs that would result
from avoiding obesity-related diseases and co-morbidity.

"Today's report supports our belief that, while there are substantial
near-term benefits of weight loss for obese patients, an even larger value
should accrue to individuals and societies when health improvements are
assessed over a longer period of time," said Orexigen CEO, Michael Narachi.

The report's author, Alex Brill, is a Research Fellow at the American
Enterprise Institute and formerly counsel to the Simpson-Bowles Deficit
Reduction Commission and chief economist and policy director to the House Ways
and Means Committee. Mr. Brill also served on the President's Council of
Economic Advisers under President George W. Bush. Mr. Brill has worked on a
variety of economic and legislative policy issues, including dividend
taxation, the alternative minimum tax, international tax policy, social
security reform, defined benefit pension reform and U.S. trade policy.

The report may be found at the Campaign to End Obesity's website

About Orexigen Therapeutics

Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the
treatment of obesity. The Company's lead product candidate is Contrave®, which
has completed Phase 3 clinical trials and for which a New Drug Application has
been submitted and reviewed by the FDA. The Company has also reached agreement
with the FDA on a Special Protocol Assessment (SPA) for the Light Study, the
Contrave cardiovascular outcomes trial. The Company's other product candidate,
Empatic™, has completed Phase 2 clinical trials. Further information about the
Company can be found at www.orexigen.com.

Contact: McDavid Stilwell, 858-875-8600

SOURCE Orexigen Therapeutics, Inc.

Website: http://www.orexigen.com
Press spacebar to pause and continue. Press esc to stop.